BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 29, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Intra-Cellular Therapies patents SERT, 5-HT2A and dopamine receptor ligands
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Intra-Cellular Therapies patents SERT, 5-HT2A and dopamine receptor ligands
Oct. 9, 2023
No Comments
Intra-Cellular Therapies Inc. has patented compounds acting as serotonin transporter (SERT), 5-HT2A, dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.
BioWorld Science
Neurology/psychiatric
Patents